MRI to differentiate multiple sclerosis, neuromyelitis optica, and myelin oligodendrocyte glycoprotein antibody disease
Journal of Neuroimaging · 2023-09 · 33 (5) · 688-702
DOI: 10.1111/jon.13137 ↗At a glance
Übersichtsarbeit in Journal of Neuroimaging, published online on 2023-06-15. Written by Edgar Carnero Contentti and 5 co-authors. Institution: Neuroimmunology Unit, Department of Neurosciences, Hospital Alemán, Buenos Aires, Argentina. Major MEDLINE topics: Neuromyelitis Optica, Multiple Sclerosis. Cited 42 times so far (Crossref); 126 references.
Abstract (original language)
Differentiating multiple sclerosis (MS) from other relapsing inflammatory autoimmune diseases of the central nervous system such as neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody‐associated disease (MOGAD) is crucial in clinical practice. The differential diagnosis may be challenging but making the correct ultimate diagnosis is critical, since prognosis and treatments differ, and inappropriate therapy may promote disability. In the last two decades, significant advances have been made in MS, NMOSD, and MOGAD including new diagnostic criteria with better characterization of typical clinical symptoms and suggestive imaging (magnetic resonance imaging [MRI]) lesions. MRI is invaluable in making the ultimate diagnosis. An increasing amount of new evidence with respect to the specificity of observed lesions as well as the associated dynamic changes in the acute and follow‐up phase in each condition has been reported in distinct studies recently published. Additionally, differences in brain (including the optic nerve) and spinal cord lesion patterns between MS, aquaporin4‐antibody‐positive NMOSD, and MOGAD have been described. We therefore present a narrative review on the most relevant findings in brain, spinal cord, and optic nerve lesions on conventional MRI for distinguishing adult patients with MS from NMOSD and MOGAD in clinical practice. In this context, cortical and central vein sign lesions, brain and spinal cord lesions characteristic of MS, NMOSD, and MOGAD, optic nerve involvement, role of MRI at follow‐up, and new proposed diagnostic criteria to differentiate MS from NMOSD and MOGAD were discussed.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Neuroimmunology Unit, Department of Neurosciences, Hospital Alemán, Buenos Aires, Argentina.
- Department of Neurology, Neuroinnovation Program, Multiple Sclerosis & Neuroimmunology Imaging Program, The University of Texas Southwestern Medical Center, Dallas, Texas, USA.
- Centro de esclerosis múltiple de Buenos Aires, Buenos Aires, Argentina.
- NeuroCure Clinical Research Center, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
- Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine and Charité-Universitätsmedizin Berlin, Berlin, Germany.
- Centro Universitario de Esclerosis Múltiple (CUEM), Hospital Ramos Mejía, Buenos Aires, Argentina.
ORCID profiles: Edgar Carnero Contentti, Darin T Okuda, Claudia Chien
Cite
APA
Carnero Contentti, E., Okuda, D. T., Rojas, J. I., Chien, C., Paul, F., & Alonso, R. (2023). MRI to differentiate multiple sclerosis, neuromyelitis optica, and myelin oligodendrocyte glycoprotein antibody disease. Journal of Neuroimaging, 33(5), 688-702. https://doi.org/10.1111/jon.13137
Vancouver
Carnero Contentti E, Okuda DT, Rojas JI, Chien C, Paul F, Alonso R. MRI to differentiate multiple sclerosis, neuromyelitis optica, and myelin oligodendrocyte glycoprotein antibody disease. Journal of Neuroimaging. 2023;33(5):688-702. doi:10.1111/jon.13137
BibTeX
@article{CarneroContentti2023,
author = {Carnero Contentti, Edgar and Okuda, Darin T and Rojas, Juan I and Chien, Claudia and Paul, Friedemman and Alonso, Ricardo},
title = {MRI to differentiate multiple sclerosis, neuromyelitis optica, and myelin oligodendrocyte glycoprotein antibody disease},
journal = {Journal of Neuroimaging},
year = {2023},
volume = {33},
number = {5},
pages = {688--702},
doi = {10.1111/jon.13137}
}
EUVIMED